Table 1.
Summary of literature on combined allopurinol and 6-mercaptopurine therapy in ALL.
| Publication | No. treated | No. responding (%) | Indications for allopurinol | Allopurinol dose | Mean 6-MP dose reduction |
|---|---|---|---|---|---|
| Stuckert et al. (19) | 19 | 18 (95) | Skewed 6-MP metabolites plus elevated ANC or hepatotoxicity | 50 mg/m2/day | 54% |
| Zhang et al. (28) | 2 | 2 (100) | Hypoglycemia | 50 mg daily | 74.5% |
| Miller et al. (27) | 2 | 2 (100) | Hypoglycemia | 50 mg/m2 or 50 mg daily | 63% |
| Giamanco et al. (30) | 2 | 2 (100) | Hepatotoxicity | 4 mg/kg/day | 48% |
| Zerra et al. (31) | 2 | 2 (100) | Pancreatitis | 50 mg twice daily | 66% |
| Brackett et al. (32) | 3 | 3 (100) | Hyperbilirubinemia Elevated 6-MMP | 50 mg/m2/day | 52% |
Composite data from six series including reason for allopurinol therapy, allopurinol and 6-MP doses, and responses achieved.